--- title: "Burden and adherence to long-term anti-VEGF intravitreal injections for retinal disease: qualitati" id: "bmj-open-11-treatment-burden-and-adherence-in-adults-receiving-long-term-anti-vegf" canonical_url: "https://medichelpline.com/clinical-feed/bmj-open-11-treatment-burden-and-adherence-in-adults-receiving-long-term-anti-vegf" content_type: "clinical_feed_article" specialty: "General" source_name: "BMJ Open" source_url: "http://bmjopen.bmj.com/cgi/content/short/16/9/e125908?rss=1" published_at: "2026-09-21T12:57:18.000Z" evidence_level: "Journal Feed" license: "CC-BY-NC-4.0 / Informational Use" --- # Burden and adherence to long-term anti-VEGF intravitreal injections for retinal disease: qualitati ## Provenance & Clinical Metadata - **Canonical URL:** https://medichelpline.com/clinical-feed/bmj-open-11-treatment-burden-and-adherence-in-adults-receiving-long-term-anti-vegf - **Specialty:** [General](https://medichelpline.com/clinical-feed/general.md) - **Primary Source:** BMJ Open - **Source URL:** [Original Journal Publication](http://bmjopen.bmj.com/cgi/content/short/16/9/e125908?rss=1) - **Published At:** 2026-09-21T12:57:18.000Z - **Evidence Rating:** Journal Feed ## Executive GIST (TL;DR) - Retinal conditions such as neovascular age-related macular degeneration and diabetic macular oedema require long-term intravitreal **anti-VEGF** injections, which can cause sustained physical, psychological, social and financial burden. - Repeated treatment burden is linked to reduced **adherence** and worse real-world visual outcomes, but quantitative studies do not explain patients' perspectives on persistence, struggle or discontinuation. - This protocol outlines a qualitative evidence synthesis to identify, appraise and synthesise primary qualitative studies (and extractable qualitative components of mixed-methods studies) addressing adults (≥18 years) receiving long-term anti-VEGF therapy for **retinal disease**. - The review follows PRISMA-P for protocol reporting and will report the completed synthesis using ENTREQ. Thomas and Harden's three-stage thematic synthesis and the Population, Phenomenon of Interest, Context and Study design (PPCSD) framework will guide analysis. - Searches were initially run across nine databases (PubMed, Embase, CINAHL, PsycINFO, Web of Science, Scopus, CNKI, Wanfang Data and SinoMed) from inception between 31 May and 2 June 2026, with planned updates; citation tracking and thesis-repository searches will supplement database searches. - Two independent reviewers will screen records, extract data and appraise study quality using the Joanna Briggs Institute checklist; disagreements resolved by a third reviewer. - Confidence in findings will be assessed using GRADE-CERQual (Grading of Recommendations Assessment, Development and Evaluation–Confidence in the Evidence from Reviews of Qualitative research). - Patient and family advisers (six to eight patients and up to two family advisers) will help interpret preliminary themes and develop a plain-language summary. - No ethical approval is required because only published data are used; findings will be disseminated via peer-reviewed publication and conference presentation. The review is registered on PROSPERO (CRD420261405614). ## Clinical Analysis & Structured Key Points Introduction Retinal diseases such as neovascular age-related macular degeneration and diabetic macular oedema are leading causes of irreversible vision loss and require intravitreal anti-vascular endothelial growth factor (VEGF) injections over many years. Repeated treatment imposes physical, psychological, social and financial burdens and is associated with reduced adherence and poorer real-world outcomes. Existing research is largely quantitative and does not explain, from patients' perspectives, why people persist with, struggle against or discontinue burdensome treatment. This review will identify, appraise and synthesise qualitative studies to understand the burden of long-term anti-VEGF therapy, how it shapes adherence and the implications for patient-centred nursing care, shared decision-making and injection-service design. Methods and analysis This protocol is reported in accordance with Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P); the completed synthesis will be reported following Enhancing Transparency in Reporting the Synthesis of Qualitative Research. We will use Thomas and Harden's three-stage thematic synthesis and the Population, Phenomenon of Interest, Context and Study design framework. Eligible studies are primary qualitative studies and independently extractable qualitative components of mixed-methods studies involving adults (≥18 years) receiving long-term anti-VEGF therapy for retinal disease, irrespective of publication language. Initial searches of nine databases (PubMed, Embase, CINAHL, PsycINFO, Web of Science, Scopus, CNKI, Wanfang Data and SinoMed) were conducted from inception between 31 May and 2 June 2026 and will be updated before completion of the review. Citation tracking and thesis-repository searches will supplement the database searches. Two reviewers will independently screen records, extract data and appraise quality using the Joanna Briggs Institute checklist, with disagreements resolved by a third reviewer. Confidence in each finding will be assessed using Grading of Recommendations Assessment, Development and Evaluation-Confidence in the Evidence from Reviews of Qualitative research. Ethics and dissemination Ethical approval is not required because the review uses published data. Six to eight patients, with up to two family advisers, will help interpret preliminary themes and develop a plain-language summary. Findings will be disseminated through peer-reviewed publication and conference presentation. PROSPERO registration number CRD420261405614. ## Related Clinical Research - [Spatio-temporal imaging and acute manipulation of endogenous Yap1 in medaka using a Yap1-mGreenLan](https://medichelpline.com/clinical-feed/biorxiv-17-spatio-temporal-visualisation-and-manipulation-of-endogenous-yap1-in-medaka.md) - [Non-retinoid RBP4 antagonist AKR-XI-85 as a candidate therapy for Stargardt disease](https://medichelpline.com/clinical-feed/biorxiv-19-a-non-retinoid-triazolopyrimidine-rbp4-antagonist-for-the-treatment-of.md) - [Reduce Gun Access to Prevent Suicide: Evidence and Policy Options](https://medichelpline.com/clinical-feed/kff-health-news-0-it-s-hard-to-predict-who-will-be-suicidal-it-s-easier-to-ensure-people-can-t.md) - [Kratom and 7‑OH dependence drives surge in addiction clinic visits](https://medichelpline.com/clinical-feed/stat-news-6-addiction-clinics-see-rising-cases-of-kratom-and-7-oh-withdrawal.md) - [Add a pregnancy and lactation checkbox to ClinicalTrials.gov](https://medichelpline.com/clinical-feed/stat-news-7-opinion-clinicaltrials-gov-needs-a-pregnancy-and-lactation-checkbox.md) ## Navigation - [← Back to General Feed](https://medichelpline.com/clinical-feed/general.md) - [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md) ## Medical & Regulatory Disclaimer > [!CAUTION] > MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations. > Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.